| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anders Abildgaard, Tina Parkner, Cindy Soendersoe Knudsen, Hanne Gottrup, Henriette Kli. Diagnostic Cut-offs for CSF β-amyloid and Tau Proteins in a Danish Dementia Clinic. Clinica chimica acta; international journal of clinical chemistry. 2022-12-26. PMID:36572135. |
analysis of beta-amyloid 1-42 (aβ42), total tau (t-tau) and phosphorylated-tau 181 (p-tau) in the cerebrospinal fluid (csf) is often performed as a part of the diagnostic work-up in case of suspected alzheimer's dementia (ad). |
2022-12-26 |
2023-08-14 |
Not clear |
| Dilek Mercan, Michael Thomas Henek. The Contribution of the Locus Coeruleus-Noradrenaline System Degeneration during the Progression of Alzheimer's Disease. Biology. vol 11. issue 12. 2022-12-23. PMID:36552331. |
alzheimer's disease (ad), which is characterized by extracellular accumulation of amyloid-beta peptide and intracellular aggregation of hyperphosphorylated tau, is the most common form of dementia. |
2022-12-23 |
2023-08-14 |
Not clear |
| Isabelle Journe-Mallet, Julien Gouju, Frédérique Etcharry-Bouyx, Valérie Chauvire, Virginie Guillet-Pichon, Clarisse Scherer-Gagou, Adriana Prundean, Sophie Godard, Aldéric Lecluse, Julien Cassereau, Christophe Verny, Franck Letournel, Philippe Codro. Design and application of a customizable relational DataBase to assess clinicopathological correlations and concomitant pathology in neurodegenerative diseases. Brain pathology (Zurich, Switzerland). 2022-12-20. PMID:36536531. |
we observed a particularly high rate of co-pathology in patients with dementia with lewy bodies (81.3% of associated tau and amyloid-β pathology) and creutzfeldt-jakob disease (68.4% of associated tau pathology). |
2022-12-20 |
2023-08-14 |
Not clear |
| Vani Jangra, Jeshnu Topl. Can Alzheimer's Disease Be Secondary to Type-2 Diabetes Mellitus? Cureus. vol 14. issue 11. 2022-12-12. PMID:36505102. |
thirdly, several pathological research has also shown that beta-amyloid plaques, hyperphosphorylated tau protein, and brain shrinkage, particularly in the hippocampus, are shared brain lesions between insulin and alzheimer's disease. in light of this, type 2 diabetes mellitus may be viewed as a liability for dementia and alzheimer's disease. |
2022-12-12 |
2023-08-14 |
human |
| In Gyoung Ju, Su Young Son, Seungmin Lee, Hyeri Im, Eugene Huh, Hyeyoon Eo, Jin Gyu Choi, Mi Won Sohn, Sung-Vin Yim, Sun Yeou Kim, Dong-Hyun Kim, Choong Hwan Lee, Myung Sook O. Protective effects of CCL01 against Aβ-induced neurotoxicity in 5xFAD transgenic mouse model of Alzheimer's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 158. 2022-12-12. PMID:36508997. |
alzheimer's disease (ad) is the most common dementia characterized by the excessive accumulation of amyloid-beta (aβ) and tau aggregates, as well as neuronal damage and neuroinflammation. |
2022-12-12 |
2023-08-14 |
mouse |
| Desh Deepak Singh, Ali A Shati, Mohammad Y Alfaifi, Serag Eldin I Elbehairi, Ihn Han, Eun-Ha Choi, Dharmendra K Yada. Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development. Cells. vol 11. issue 23. 2022-12-11. PMID:36497027. |
we discuss the pathological and physiological mechanisms behind the association between type 2 diabetes mellitus and dementia, such as insulin resistance, insulin signaling, and sporadic forms of dementia; the relationship between insulin receptor activation and tau phosphorylation; dementia and mrna expression and downregulation of related receptors; neural modulation due to insulin secretion and glucose homeostasis; and neuronal apoptosis due to insulin resistance and type 2 diabetes mellitus. |
2022-12-11 |
2023-08-14 |
Not clear |
| Kseniya B Varshavskaya, Vladimir A Mitkevich, Alexander A Makarov, Evgeny P Baryki. Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer's Disease for Research and Drug Development. International journal of molecular sciences. vol 23. issue 23. 2022-12-11. PMID:36499362. |
alzheimer's disease (ad) is the most common cause of dementia in the elderly, characterised by the accumulation of senile plaques and tau tangles, neurodegeneration, and neuroinflammation in the brain. |
2022-12-11 |
2023-08-14 |
Not clear |
| Norman A Mazer, Carsten Hofmann, Dominik Lott, Ronald Gieschke, Gregory Klein, Frank Boess, Hans Peter Grimm, Geoffrey A Kerchner, Monika Baudler-Klein, Janice Smith, Rachelle S Dood. Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022-12-01. PMID:36454709. |
a quantitative model of alzheimer's disease (ad) based on the amyloid/tau/neurodegeneration biomarker framework (q-atn model) was developed to sequentially link amyloid positron emission tomography (pet), tau pet, medial temporal cortical thickness, and clinical outcome (clinical dementia rating - sum of boxes; cdr-sb). |
2022-12-01 |
2023-08-14 |
Not clear |
| Li-Lin Chen, Yong-Gang Fan, Ling-Xiao Zhao, Qi Zhang, Zhan-You Wan. The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. Bioorganic chemistry. vol 131. 2022-12-01. PMID:36455485. |
alzheimer's disease (ad), characterized by the β-amyloid protein (aβ) deposition and tau hyperphosphorylation, is the most common dementia with uncertain etiology. |
2022-12-01 |
2023-08-14 |
Not clear |
| Aidong Yuan, Ralph A Nixo. Posttranscriptional regulation of neurofilament proteins and tau in health and disease. Brain research bulletin. vol 192. 2022-11-28. PMID:36441047. |
neurofilament and tau proteins are neuron-specific cytoskeletal proteins that are enriched in axons, regulated by many of the same protein kinases, interact physically, and are the principal constituents of neurofibrillary lesions in major adult-onset dementias. |
2022-11-28 |
2023-08-14 |
Not clear |
| Daniel Ferreira, Scott A Przybelski, Timothy G Lesnick, Christopher G Schwarz, Patricia Diaz-Galvan, Jonathan Graff-Radford, Matthew L Senjem, Julie A Fields, David S Knopman, David T Jones, Rodolfo Savica, Tanis J Ferman, Neill Graff-Radford, Val J Lowe, Clifford R Jack, Ronald C Petersen, Eric Westman, Brad F Boeve, Kejal Kantarc. Cross-sectional Associations of β-Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies. Neurology. 2022-11-28. PMID:36443011. |
cross-sectional associations of β-amyloid, tau, and cerebrovascular biomarkers with neurodegeneration in probable dementia with lewy bodies. |
2022-11-28 |
2023-08-14 |
Not clear |
| Brandon C Yarns, Kelsey A Holiday, David M Carlson, Coleman K Cosgrove, Rebecca J Melros. Pathophysiology of Alzheimer's Disease. The Psychiatric clinics of North America. vol 45. issue 4. 2022-11-17. PMID:36396271. |
while neuritic plaques consisting of aggregated amyloid-beta proteins and neurofibrillary tangles of accumulated tau proteins represent the pathophysiologic hallmarks of ad, numerous processes likely interact with risk and protective factors and one's culture to produce the cognitive loss, neuropsychiatric symptoms, and functional impairments that characterize ad dementia. |
2022-11-17 |
2023-08-14 |
Not clear |
| Edward N Wilson, Christina B Young, Javier Ramos Benitez, Michelle S Swarovski, Igor Feinstein, Manu Vandijck, Yann Le Guen, Nandita M Kasireddy, Marian Shahid, Nicole K Corso, Qian Wang, Gabriel Kennedy, Alexandra N Trelle, Betty Lind, Divya Channappa, Malia Belnap, Veronica Ramirez, Irina Skylar-Scott, Kyan Younes, Maya V Yutsis, Nathalie Le Bastard, Joseph F Quinn, Christopher H van Dyck, Angus Nairn, Carolyn A Fredericks, Lu Tian, Geoffrey A Kerchner, Thomas J Montine, Sharon J Sha, Guido Davidzon, Victor W Henderson, Frank M Longo, Michael D Greicius, Anthony D Wagner, Tony Wyss-Coray, Kathleen L Poston, Elizabeth C Mormino, Katrin I Andreasso. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease. Alzheimer's research & therapy. vol 14. issue 1. 2022-11-12. PMID:36371232. |
advances in the development of novel blood-based biomarkers for ad have revealed that plasma levels of tau phosphorylated at various residues are specific and sensitive to ad dementia. |
2022-11-12 |
2023-08-14 |
Not clear |
| Yilin Tang, Ling Li, Tianyu Hu, Fangyang Jiao, Linlin Han, Shiyu Li, Zhiheng Xu, Yun Fan, Yimin Sun, Fengtao Liu, Tzu-Chen Yen, Chuantao Zuo, Jian Wan. In Vivo Movement disorders : official journal of the Movement Disorder Society. 2022-11-11. PMID:36368769. |
in vivo tau pathology is observed during autopsy in many patients with parkinson's disease dementia (pdd). |
2022-11-11 |
2023-08-14 |
Not clear |
| Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Ruben Smith, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Pontus Tideman, Tomas Ohlsson, Jonas Jögi, Keith Johnson, Reisa Sperling, Vincent Dore, Colin L Masters, Christopher Rowe, Denise Visser, Bart N M van Berckel, Wiesje M van der Flier, Suzanne Baker, William J Jagust, Heather J Wiste, Ronald C Petersen, Clifford R Jack, Oskar Hansso. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature medicine. 2022-11-10. PMID:36357681. |
a major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both alzheimer's disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. |
2022-11-10 |
2023-08-14 |
Not clear |
| Steffen Pockes, Michael A Walters, Karen H Ash. Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias. Translational research : the journal of laboratory and clinical medicine. 2022-11-07. PMID:36343883. |
targeting caspase-2 interactions with tau in alzheimer's disease and related dementias. |
2022-11-07 |
2023-08-14 |
Not clear |
| Steffen Pockes, Michael A Walters, Karen H Ash. Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias. Translational research : the journal of laboratory and clinical medicine. 2022-11-07. PMID:36343883. |
targeting amyloid-β plaques and tau tangles has failed to provide effective treatments for alzheimer's disease and related dementias (adrd). |
2022-11-07 |
2023-08-14 |
Not clear |
| Kausalia Vijayaragavan, Bryan J Cannon, Dmitry Tebaykin, Marc Bossé, Alex Baranski, J P Oliveria, Syed A Bukhari, Dunja Mrdjen, M Ryan Corces, Erin F McCaffrey, Noah F Greenwald, Yari Sigal, Diana Marquez, Zumana Khair, Trevor Bruce, Mako Goldston, Anusha Bharadwaj, Kathleen S Montine, R Michael Angelo, Thomas J Montine, Sean C Bendal. Single-cell spatial proteomic imaging for human neuropathology. Acta neuropathologica communications. vol 10. issue 1. 2022-11-05. PMID:36333818. |
we show microglia-pathologic tau interactions in hippocampal ca1 subfield in ad dementia. |
2022-11-05 |
2023-08-14 |
human |
| Gerard J Nuovo, David Suster, Dwitiya Sawant, Aditi Mishra, Jean-Jacques Michaille, Esmerina Til. The amplification of CNS damage in Alzheimer's disease due to SARS-CoV2 infection. Annals of diagnostic pathology. vol 61. 2022-11-05. PMID:36334414. |
immunohistochemistry analyses for hyperphosphorylated tau protein, α-synuclein, and β-amyloid-42 confirmed the diagnoses of alzheimer's disease (n = 4), and lewy body dementia (n = 1) in the covid-19 group. |
2022-11-05 |
2023-08-14 |
human |
| Gerard J Nuovo, David Suster, Dwitiya Sawant, Aditi Mishra, Jean-Jacques Michaille, Esmerina Til. The amplification of CNS damage in Alzheimer's disease due to SARS-CoV2 infection. Annals of diagnostic pathology. vol 61. 2022-11-05. PMID:36334414. |
in covid-19 tissues from people with dementia the widespread spike-induced microencephalitis with the concomitant microglial activation co-existed in the same areas where neurons had hyperphosphorylated tau protein suggesting that the already dysfunctional neurons were additionally stressed by the sars-cov2 induced microangiopathy. |
2022-11-05 |
2023-08-14 |
human |